These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8745224)

  • 1. Expression of inducible nitric oxide synthase in failing and non-failing human heart.
    Thoenes M; Förstermann U; Tracey WR; Bleese NM; Nüssler AK; Scholz H; Stein B
    J Mol Cell Cardiol; 1996 Jan; 28(1):165-9. PubMed ID: 8745224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure.
    Stein B; Eschenhagen T; Rüdiger J; Scholz H; Förstermann U; Gath I
    J Am Coll Cardiol; 1998 Nov; 32(5):1179-86. PubMed ID: 9809923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of inducible nitric oxide synthase in human heart failure.
    Haywood GA; Tsao PS; von der Leyen HE; Mann MJ; Keeling PJ; Trindade PT; Lewis NP; Byrne CD; Rickenbacher PR; Bishopric NH; Cooke JP; McKenna WJ; Fowler MB
    Circulation; 1996 Mar; 93(6):1087-94. PubMed ID: 8653828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure.
    Vejlstrup NG; Bouloumie A; Boesgaard S; Andersen CB; Nielsen-Kudsk JE; Mortensen SA; Kent JD; Harrison DG; Busse R; Aldershvile J
    J Mol Cell Cardiol; 1998 Jun; 30(6):1215-23. PubMed ID: 9689595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression of antioxidative enzymes in the human heart: increased expression of catalase in the end-stage failing heart.
    Dieterich S; Bieligk U; Beulich K; Hasenfuss G; Prestle J
    Circulation; 2000 Jan 4-11; 101(1):33-9. PubMed ID: 10618301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in end-stage human heart failure: their relation to lesion site and beta-adrenergic receptor therapy.
    Fukuchi M; Hussain SN; Giaid A
    Circulation; 1998 Jul; 98(2):132-9. PubMed ID: 9679719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart.
    Drexler H; Kästner S; Strobel A; Studer R; Brodde OE; Hasenfuss G
    J Am Coll Cardiol; 1998 Oct; 32(4):955-63. PubMed ID: 9768717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure.
    Kuoppala A; Shiota N; Kokkonen JO; Liesmaa I; Kostner K; Mäyränpää M; Kovanen PT; Lindstedt KA
    J Am Coll Cardiol; 2002 Jul; 40(1):119-25. PubMed ID: 12103265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine-induced nitric oxide inhibits mitochondrial energy production and induces myocardial dysfunction in endotoxin-treated rat hearts.
    Tatsumi T; Akashi K; Keira N; Matoba S; Mano A; Shiraishi J; Yamanaka S; Kobara M; Hibino N; Hosokawa S; Asayama J; Fushiki S; Fliss H; Nakagawa M; Matsubara H
    J Mol Cell Cardiol; 2004 Sep; 37(3):775-84. PubMed ID: 15350850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA).
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Grisorio B; Pellicelli A; Barbarini G
    Circulation; 1999 Aug; 100(9):933-9. PubMed ID: 10468523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvar heart disease.
    de Belder AJ; Radomski MW; Why HJ; Richardson PJ; Martin JF
    Br Heart J; 1995 Oct; 74(4):426-30. PubMed ID: 7488459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE2 gene expression is up-regulated in the human failing heart.
    Goulter AB; Goddard MJ; Allen JC; Clark KL
    BMC Med; 2004 May; 2():19. PubMed ID: 15151696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducible nitric oxide synthase contributes to intermittent hypoxia against ischemia/reperfusion injury.
    Ding HL; Zhu HF; Dong JW; Zhu WZ; Yang WW; Yang HT; Zhou ZN
    Acta Pharmacol Sin; 2005 Mar; 26(3):315-22. PubMed ID: 15715927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of inducible nitric oxide synthase is increased in patients with heart failure due to ischemic disease.
    Ferreiro CR; Chagas AC; Carvalho MH; Dantas AP; Scavone C; Souza LC; Buffolo E; da Luz PL
    Braz J Med Biol Res; 2004 Sep; 37(9):1313-20. PubMed ID: 15334196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPK isoform expression in the normal and failing hearts.
    Kim M; Shen M; Ngoy S; Karamanlidis G; Liao R; Tian R
    J Mol Cell Cardiol; 2012 May; 52(5):1066-73. PubMed ID: 22314372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inhibitor of nitric oxide synthase does not increase contraction or beta-adrenoceptor sensitivity of ventricular myocytes from failing human heart.
    Harding SE; Davies CH; Money-Kyrle AM; Poole-Wilson PA
    Cardiovasc Res; 1998 Dec; 40(3):523-9. PubMed ID: 10070493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart.
    Patten RD; Denofrio D; El-Zaru M; Kakkar R; Saunders J; Celestin F; Warner K; Rastegar H; Khabbaz KR; Udelson JE; Konstam MA; Karas RH
    J Am Coll Cardiol; 2005 May; 45(9):1419-24. PubMed ID: 15862412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium.
    Moniotte S; Kobzik L; Feron O; Trochu JN; Gauthier C; Balligand JL
    Circulation; 2001 Mar; 103(12):1649-55. PubMed ID: 11273992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure.
    Schmidt U; Hajjar RJ; Helm PA; Kim CS; Doye AA; Gwathmey JK
    J Mol Cell Cardiol; 1998 Oct; 30(10):1929-37. PubMed ID: 9799647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium.
    Asano K; Dutcher DL; Port JD; Minobe WA; Tremmel KD; Roden RL; Bohlmeyer TJ; Bush EW; Jenkin MJ; Abraham WT; Raynolds MV; Zisman LS; Perryman MB; Bristow MR
    Circulation; 1997 Mar; 95(5):1193-200. PubMed ID: 9054849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.